• Skip to main content
  • Skip to primary sidebar
  • Home
  • News
  • Events
  • Education
  • Interviews
    • Career spotlight
  • Opinion
    • Professional Dilemmas
    • Patient perspective
  • PIPcast
  • Jobs
  • Business Directory

Pharmacy in Practice

EDX/20/1154
Date of prep: December 2020

Prescribing information and
adverse events reporting

For healthcare professionals only

New use found for old diabetes medicine

15th October 2020 by PIP editor Leave a Comment

 

Work by pharmaceutical scientists in Japan has found that the thiazolidinedione troglitazone inhibits internalisation of hepatitis B virus (HBV). “Current anti-HBV agents, including nucleoside analogues and interferons, can reduce viral load, but are not generally curative. Thus, the development of anti-HBV agents with different modes of action is required to improve treatment outcomes,” said Kento Fukano of the National Institute of Infectious Diseases, Japan.

 

The research was presented at the Pharmaceutical Sciences World Congress, which was held online this week by the International Pharmaceutical Federation (FIP). “Virus internalisation into host cells is the initial step of infection, which means that this compound could be used for post-exposure prophylaxis. However, as viral entry is also essential for the initiation, spread and maintenance of viral infection, troglitazone is also a potential treatment for chronic hepatitis B,” Dr Fukano explained.

In addition, a mechanism of action has been identified: troglitazone was found to clearly impede the oligomerisation of NTCP (sodium taurocholate cotransporting polypeptide), which is an entry receptor. “These results suggest that the oligomerisation of NTCP has potential to regulate HBV internalisation and it can serve as a new target for the development of anti-HBV agents,” Dr Fukano added.

According to the researchers, troglitazone is the first small molecule that has been shown to act in this way, potentially expanding the landscape of treatment options. “Hepatitis B immunoglobulin (HBIG) is a human-derived antibody that can neutralise infection. It is currently the only entry inhibitor to have obtained approval for treatment, but its use is limited by cost and supply issues as HBIG is obtained from vaccinated human donors. In contrast, troglitazone is cheap, we can maintain a more stable supply, and it can be administered orally, which is an advantage for developing countries with scarce medical resources,” Dr Fukano explained.

 

You can view the research poster here. 

 

 

Share this:

  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to share on Twitter (Opens in new window)
  • Click to share on WhatsApp (Opens in new window)
  • Click to share on Telegram (Opens in new window)
  • Click to email this to a friend (Opens in new window)

Related

Next article  GPhC publish new pharmacist education and training standards

Filed Under: News Tagged With: Diabetes, Hep B

Register for our upcoming webinar and live Q&A

About PIP editor

Pharmacy in Practice is a UK pharmacy publication with its roots in Scotland.

Reader Interactions

Begin the discussion right here Cancel reply

Primary Sidebar

Categories

Follow Us

  • Twitter
  • LinkedIn
  • Facebook
  • Instagram
  • Twitter

PIP business directory

Letters to the editor

Letters to the editor

Pharmacies should be allowed to supply rapid antibody tests

Admiration for community pharmacy in Scotland

The ‘ART’ of Scottish community pharmacy is all about data

Pharmacists must leave their comfort zone for the sector to thrive

More letters to the editor here...

Blogs

💊 PIP live pharmacy blog

Winter stresses must not ‘destabilise’ general practice

What is it like to depend on medicine to treat endometriosis?

Opinion

Why is pharmacy not integral to government mass vaccination plans?

Pharmacy Covid-19 vaccination involvement is a ‘no-brainer’

The great patient medication returns debacle

CPD Challenges

💊 CPD Challenge: How well do you understand pulmonary embolisms?

💊 CPD Challenge: Prescribing and dispensing clozapine

💊 CPD Challenge: Oral anticoagulants – Dabigatran

More CPD challenges here...

© 2021 · About Pharmacy In Practice · Site mantained by Mike

This site is for healthcare professionals, please confirm you are a healthcare professional to continue.

YES

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
Pharmacy In Practice uses cookies, by continuing to use this site we will assume you are ok with that Find out more.